Theravance Biopharma, INC

Theravance Biopharma, Inc. announced the completion of its merger with Zymeworks Inc., with shareholders receiving $17.00 in cash and a contingent value right per share.

Theravance Biopharma announced that its shareholders overwhelmingly approved the merger agreement with Zymeworks Inc. at an extraordinary general meeting.

Theravance Biopharma has filed supplemental disclosures to its proxy statement in response to shareholder litigation concerning its proposed merger with Zymeworks, aiming to avoid delays.

Theravance Biopharma announced that its Phase 3 CYPRESS Study for ampreloxetine in symptomatic neurogenic orthostatic hypotension did not meet its primary endpoint, but is engaging with the FDA on potential next steps.

Theravance Biopharma announced its second quarter 2026 financial results, highlighting an 11% year-over-year increase in YUPELRI collaboration revenue and providing an update on its pending acquisition by Zymeworks.

Theravance Biopharma, Inc. announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right (CVR) for future ampreloxetine proceeds.

Theravance Biopharma announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right, following a strategic review.

Theravance Biopharma announced first-quarter 2026 financial results, reporting a net loss of $4.9 million, and confirmed the wind-down of its ampreloxetine program following unsuccessful Phase 3 trial results.

Theravance Biopharma reported a significant net income for the nine months ended September 30, 2025, driven by a $75.1 million gain from the sale of its remaining TRELEGY royalties to GSK, while advancing its ampreloxetine Phase 3 study.

Theravance Biopharma reported significant net income and cash flow for Q2 2025, driven by a $225 million sale of TRELEGY royalties to GSK and continued growth in YUPELRI sales.

Theravance Biopharma announces its Q1 2025 financial results, highlighting revenue growth from YUPELRI and advancements in the ampreloxetine clinical program.

Theravance Biopharma's Q3 2024 results show a net loss of $12.7 million, but YUPELRI sales hit a record high, driven by increased demand and market share.

Theravance Biopharma announced the wind-down of its ampreloxetine program following Phase 3 study failure, accelerating a strategic review while focusing on YUPELRI's continued sales growth and cost-cutting restructuring.

Theravance Biopharma's 2024 10-K filing highlights YUPELRI's net sales growth, continued progress in the Ampreloxetine Phase 3 clinical study, and a strategic review to unlock shareholder value.

Theravance Biopharma's 2023 annual report showcases YUPELRI's sales growth and the advancement of ampreloxetine into a new Phase 3 clinical study.

Weiss Asset Management LP and 2 others reported changes in beneficial ownership of Theravance Biopharma, Inc. common stock on September 23, 2026.

Deepika Pakianathan, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.

Donal O'Connor, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.

Dean J Mitchell, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.

Susannah Gray, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.

Alsup Laurie Smaldone, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.

Theravance Biopharma announces its 2026 Annual General Meeting to be held on June 12, 2026, in Dublin, Ireland.

Theravance Biopharma will hold its 2025 Annual General Meeting on May 19, 2025, in Dublin, Ireland, to vote on director elections, auditor ratification, and executive compensation.

Theravance Biopharma will hold its 2024 Annual General Meeting on May 8, 2024, in Dublin, Ireland, to vote on director elections, auditor ratification, and executive compensation.

Weiss Asset Management LP and related entities report zero beneficial ownership of Theravance Biopharma, Inc. ordinary shares following the company's merger with Zymeworks Inc. and subsequent share cancellation.

Weiss Asset Management LP and its affiliates have increased their beneficial ownership in Theravance Biopharma, Inc. to 14.5% of outstanding shares.

Madison Avenue International LP, along with affiliated entities, has reported a beneficial ownership of 9,212,252 ordinary shares, representing 17.7% of Theravance Biopharma, Inc.

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 6.5% beneficial ownership stake in Theravance Biopharma, Inc. as of March 31, 2025.

Newtyn Management, LLC and its affiliates have disclosed a combined 9.7% beneficial ownership stake in Theravance Biopharma, Inc., as of December 31, 2024.